Application of leonurine in preparation of medicine for preventing and treating non-vascular dementia or infectious central nervous injury

A technology of leonurine and central nervous system, which is applied in the field of medicine and can solve the problems of unseen neuron effects and the like

Pending Publication Date: 2022-07-29
OCEAN UNIV OF CHINA
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] But so far, there have been no relevant reports on the effects of leonurine on AD and non-vascular dementia, let alone studies on the effect of leonurine on neurons during virus or bacterial infection invasion and transfer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of leonurine in preparation of medicine for preventing and treating non-vascular dementia or infectious central nervous injury
  • Application of leonurine in preparation of medicine for preventing and treating non-vascular dementia or infectious central nervous injury
  • Application of leonurine in preparation of medicine for preventing and treating non-vascular dementia or infectious central nervous injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1: Leonurine improves spatial learning and memory ability and spatial exploration ability of AD mice

[0042] Thirty mice were randomly divided into 5 groups with 6 mice in each group, which were (1) sham-operated group; (2) model group; (3) low-dose group (oral Leonurine 8 mg / kg); (4) high-dose group Group (oral Leonurine 80mg / kg); (5) Donepezil group (Oral donepezil 1.5mg / kg).

[0043]Dissolve amyloid Aβ1-42 with sterile physiological saline at a concentration of 500 μmol / L, and incubate in a 37°C incubator for 5 days before use. Mice were anesthetized by intraperitoneal injection of 10% chloral hydrate, and fixed on the brain stereotaxic apparatus. After routine disinfection, the middle skin of the top of the mouse head was incised, and the midline and bregma of the skull were cleaned and fully exposed, and the skull surface marker points ( The anterior fontanelle is zero point, the posterior fontanelle is 3.5mm, and the midline is 2.5mm), and a hole is dril...

Embodiment 2

[0057] Example 2: The effect of leonurine on the deposition of senile plaques in the cortex and hippocampus of AD mice

[0058] The senile dementia mouse model described in Example 1 was used, and the mice were killed by decapitation after administration, and the brain tissue was quickly taken out. The brain tissue was rinsed in ice-cold saline, dried with filter paper, and weighed. The protein lysis solution (containing PMSF) of twice the tissue weight was fully lysed with a homogenizer on ice; after lysis for 30 min, it was transferred to a centrifuge tube, centrifuged at 4°C and 12000 rpm for 5 min, and the supernatant was collected in a 1.5 ml centrifuge tube. middle. Measure the protein concentration with a protein quantifier, then adjust the protein concentration to 20 μg / μL with RIPA lysis buffer, and mix the two in a ratio of 1 μL protein loading buffer (5X) per 4 μL protein sample, 100 °C or boiling water. Heat in the bath for 3-5min and store in -20℃ refrigerator. ...

Embodiment 3

[0066] Example 3: Effects of leonurine on acetylcholine (Ach) and brain-derived nerve growth factor (BDNF) in AD mice brain

[0067] The senile dementia mouse model described in Example 1 was used, and the mice were killed by decapitation after administration, and the brain tissue was quickly taken out. The brain tissue was rinsed in ice-cold saline, dried with filter paper, and weighed. The protein lysis solution (containing PMSF) of twice the tissue weight was fully lysed with a homogenizer on ice; after lysis for 30 min, it was transferred to a centrifuge tube, centrifuged at 4°C and 12000 rpm for 5 min, and the supernatant was collected in a 1.5 ml centrifuge tube. middle. The contents of Ach and BDNF were detected by ELISA kit.

[0068] The results are shown in Table 6. Compared with the sham-operated group, the contents of Ach and BDNF in the brains of the mice in the model group were significantly reduced, while both the high and low doses of leonurine and the positive...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
Login to view more

Abstract

The invention provides application of leonurine in preparation of a medicine for preventing and treating non-vascular dementia or infectious central nervous injury. By constructing an AD animal model, the leonurine is verified to be capable of improving spatial learning memory and behavioral ability of AD animals, inhibiting phosphorylation of Tau proteins in cortex and hippocampal regions of the AD animals and reducing aggregation of Abeta proteins; an infectious central nervous injury cell model is also constructed, and it is verified that the leonurine can inhibit release of LDH, release of cytochrome c and expression of apoptosis effect protein caspase-3 and improve the responsivity of a dopamine signal channel, NQO1 enzyme, reverse enzyme activity of lipoxygenase LOX, glycogen synthase kinase GSK3beta and PDE, and the leonurine can be used for preparing an anti-inflammatory drug. Therefore, the invention verifies a new target spot and a new mechanism of the leonurine targeting PDE, and verifies a new application of the leonurine in medicines for preventing and treating non-vascular dementia or infectious central nervous injury based on the new target spot and the new mechanism.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a new use of leonurine, in particular to the application of leonurine in the preparation of a medicine for preventing and treating non-vascular dementia or infectious central nervous system injury. Background technique [0002] Dementia refers to a chronic acquired progressive intellectual disability syndrome, which is a comprehensive disease. Clinically, it is mainly characterized by a slow-onset mental decline, and its main pathological changes are senile plaques, neurofibrillary tangles and neuronal loss. Alzheimer's disease is mainly divided into three categories: Alzheimer's disease, vascular dementia and secondary dementia. [0003] Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease. It is the most common type of dementia different from vascular dementia. It is a common and frequently-occurring disease of the elderly. The onset of AD is ins...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/235A61P25/28A61P25/00A61P35/00A61P31/04A61P31/16
CPCA61K31/235A61P25/28A61P25/00A61P35/00A61P31/04A61P31/16
Inventor 郝杰杰于广利李海花管华诗
Owner OCEAN UNIV OF CHINA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap